Moreover, mutations in the PIK3 catalytic subunit alpha (PIK3CA) gene, which occur in approximately 40% of patients with HR-positive, HER2-negative breast cancer, predict worse survival outcomes. This evidence concerns the gene ERBB2 and breast cancer.